MannKind reports positive Phase 1b INFLO-1 results for inhaled nintedanib in IPF

Reuters2026/07/29 10:31

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

MannKind reported positive topline Phase 1b INFLO-1 results for nintedanib dry powder inhalation in idiopathic pulmonary fibrosis.
Trial met its primary goal, showing the inhaled therapy was generally safe and well tolerated, with no serious safety issues.
Most patients reported no cough; reported cough was mostly mild and did not drive treatment stoppages.
Additional data will be presented at a future conference.
Global Phase 2 INFLO-2 is actively enrolling, positioning the program for a larger test of safety and potential efficacy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MannKind Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607290630PRIMZONEFULLFEED9799978) on July 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

MannKind reports positive Phase 1b INFLO-1 results for inhaled nintedanib in IPF

You may also like

Crypto prices